Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 10%
Buy 20%
Hold 70%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst Inc has demonstrated significant financial growth over the past seven years, highlighted by increasing EBITDA and a growing client base, despite a reduction in headcount, indicating operational efficiency. Many hospital executives have reported that their purchasing of Health Catalyst's modules is on the rise, along with positive volume trends that are ahead of budget expectations, suggesting strong demand for the company’s offerings. Moreover, as the acute care market stabilizes from previous economic pressures and improvements in volumes are observed, there is an anticipated rise in demand for Health Catalyst’s data and analytics solutions.

Bears say

Health Catalyst Inc. is facing a negative outlook primarily due to slowing total revenue growth and a highly penetrated total addressable market (TAM), raising concerns about future revenue and EBITDA growth. The company's recent performance highlighted a modest revenue and EBITDA beat for Q3; however, the 2026 revenue guidance indicates a forecast of 2-3% year-over-year declines alongside challenges such as client migration to a lower-cost platform and pressures on margins as top-line growth stagnates. Additionally, the impending departure of CEO Dan Burton and a decline in net dollar-based retention further exacerbate uncertainties regarding the company's future commercial viability and performance.

HCAT has been analyzed by 10 analysts, with a consensus rating of Hold. 10% of analysts recommend a Strong Buy, 20% recommend Buy, 70% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 10 analysts, HCAT has a Hold consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.